Cargando…

Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk

BACKGROUND: Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM. AIM: To characterize this adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaefer, Benedikt, Würtinger, Philipp, Finkenstedt, Armin, Braithwaite, Vickie, Viveiros, André, Effenberger, Maria, Sulzbacher, Irene, Moschen, Alexander, Griesmacher, Andrea, Tilg, Herbert, Vogel, Wolfgang, Zoller, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131956/ https://www.ncbi.nlm.nih.gov/pubmed/27907058 http://dx.doi.org/10.1371/journal.pone.0167146

Ejemplares similares

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Heterozygosity for the alpha‐1‐antitrypsin Z allele in cirrhosis is associated with more advanced disease
por: Schaefer, Benedikt, et al.
Publicado: (2018)

Cloak and dagger ‐ secondary hemophygocytic lymphohistiocytosis caused by intravenous autoinfection
por: Pircher, Andreas, et al.
Publicado: (2019)

Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease
por: Viveiros, André, et al.
Publicado: (2020)

Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
por: Schaefer, Benedikt, et al.
Publicado: (2018)

Transferrin as a predictor of survival in cirrhosis
por: Viveiros, André, et al.
Publicado: (2018)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose
por: Schaefer, Benedikt, et al.
Publicado: (2021)

Intravenous Iron Induced Severe Hypophosphatemia
por: Guo, Rong R, et al.
Publicado: (2021)

Intravenous Iron Administration and Hypophosphatemia in Clinical Practice
por: Hardy, S., et al.
Publicado: (2015)

Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome
por: Glaspy, John A., et al.
Publicado: (2021)

MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes
por: Viveiros, André, et al.
Publicado: (2021)

Recurrent severe hypophosphatemia following intravenous iron administration
por: Nataatmadja, Melissa Stephanie, et al.
Publicado: (2020)

Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
por: Detlie, Trond Espen, et al.
Publicado: (2021)

Neurodegeneration in Hepatic and Neurologic Wilson’s Disease
por: Viveiros, André, et al.
Publicado: (2021)

Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021)

Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review
por: Glaspy, John A, et al.
Publicado: (2020)

Transmission of oral microbiota to the biliary tract during endoscopic retrograde cholangiography
por: Effenberger, Maria, et al.
Publicado: (2023)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Impact of preoperative anemia, iron-deficiency and inflammation on survival after colorectal surgery—A retrospective cohort study
por: Bath, Messina, et al.
Publicado: (2022)

Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage
por: Brandenburg, Vincent, et al.
Publicado: (2020)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)
por: Graziadei, Ivo, et al.
Publicado: (2016)

Dietary Factors: Major Regulators of the Gut's Microbiota
por: Moschen, Alexander R., et al.
Publicado: (2012)

Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study
por: Steinkohl, Fabian, et al.
Publicado: (2020)

Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
por: Tilg, Herbert, et al.
Publicado: (2021)

Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis
por: Effenberger, Maria, et al.
Publicado: (2021)

Oxygenation Performance of Different Non-Invasive Devices for Treatment of Decompression Illness and Carbon Monoxide Poisoning
por: Köhler, Andrea, et al.
Publicado: (2022)

[(68)Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis
por: Haubner, Roland, et al.
Publicado: (2016)

A rare case of parental iron-induced persistent hypophosphatemia
por: Sullivan, Abigayle, et al.
Publicado: (2020)

Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials
por: Fukumoto, Seiji, et al.
Publicado: (2023)

Liver stiffness by transient elastography accompanies illness severity in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2020)

Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation
por: Finkenstedt, Armin, et al.
Publicado: (2010)

Nirogacestat and Hypophosphatemia
por: Gudsoorkar, Prakash, et al.
Publicado: (2023)

Oral Iron for Prevention and Treatment of Rickets and Osteomalacia in Autosomal Dominant Hypophosphatemia
por: Högler, Wolfgang, et al.
Publicado: (2019)

98 Severe Hypophosphatemia After Iron Infusion: A Serious Complication
Publicado: (2021)

MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
por: Grabherr, Felix, et al.
Publicado: (2022)

Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation
por: Haridas, Keerthana, et al.
Publicado: (2022)

Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD
por: Klepsch, Victoria, et al.
Publicado: (2019)

Gut Dysfunction and Non-alcoholic Fatty Liver Disease
por: Grabherr, Felix, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_60he8l91j7im3ifcv7qa4e28mp